Hydrophobically Modified siRNAs Silence Huntingtin mRNA in Primary Neurons and Mouse Brain

Molecular Therapy Nucleic Acids

Volumn 4, Issue , 2015, Pages e266-

  Alterman, Julia F ^a   Hall, Lauren M ^a   Coles, Andrew H ^a   Hassler, Matthew R ^a   Didiot, Marie Cecile ^a   Chase, Kathryn ^a   Abraham, Jasmin ^a   Sottosanti, Emily ^a   Johnson, Emily ^a   Sapp, Ellen ^b   Osborn, Maire F ^a   DiFiglia, Marian ^b   Aronin, Neil ^a   Khvorova, Anastasia ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Delivery; Huntington's disease; neurodegenerative disease; RNA interference; small interfering RNA

Indexed keywords

HUNTINGTIN; HYDROPHOBICALLY MODIFIED SMALL INTERFERING RNA; LIPID; MESSENGER RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN; BRAIN CELL; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG FORMULATION; EMBRYO; FEMALE; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENE TARGETING; GENETIC MANIPULATION; HELA CELL LINE; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; INJECTION; MALE; MOUSE; NERVE CELL; NEUROSCIENCE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE;

EID: 84948734979     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2015.38     Document Type: Article

References (58)

1. Fire, A, Xu, S, Montgomery, MK, Kostas, SA, Driver, SE and Mello, CC (1998).Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811.
2. Zamore, PD (2001).RNA interference: listening to the sound of silence. Nat Struct Biol 8: 746-750.
3. Castanotto, D and Rossi, JJ (2009).The promises and pitfalls of RNA-interference-based therapeutics. Nature 457: 426-433.
4. Davidson, BL and McCray, PB Jr (2011).Current prospects for RNA interference-based therapies. Nat Rev Genet 12: 329-340.
5. Byrne, M, Tzekov, R, Wang, Y, Rodgers, A, Cardia, J, Ford, G et al. (2013).Novel hydrophobically modified asymmetric RNAi compounds (sd-rxRNA) demonstrate robust efficacy in the eye. J Ocul Pharmacol Ther 29: 855-864.
6. Miller, VM, Paulson HL, Gonzalez-Alegre, P (2005).RNA interference in neuroscience: progress and challenges. Cell Mol Neurobiol 25: 1195-1207.
7. Sah, DW and Aronin, N (2011).Oligonucleotide therapeutic approaches for Huntington disease. J Clin Invest 121: 500-507.
8. Boudreau, RL, McBride, JL, Martins, I, Shen, S, Xing, Y, Carter, BJ et al. (2009).Nonallelespecific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther 17: 1053-1063.
9. Ramachandran, PS, Boudreau, RL, Schaefer, KA, La Spada, AR and Davidson, BL (2014).Nonallele specific silencing of ataxin-7 improves disease phenotypes in a mouse model of SCA7. Mol Ther 22: 1635-1642.
10. Kumar, P, Wu, H, McBride, JL, Jung, KE, Kim, MH, Davidson, BL et al. (2007).Transvascular delivery of small interfering RNA to the central nervous system. Nature 448: 39-43.
11. Huo, H, Gao, Y, Wang, Y, Zhang, J, Wang, ZY, Jiang, T et al. (2015).Polyion complex micelles composed of pegylated polyasparthydrazide derivatives for siRNA delivery to the brain. J Colloid Interface Sci 447: 8-15.
12. DiFiglia, M, Sena-Esteves, M, Chase, K, Sapp, E, Pfister, E, Sass, M et al. (2007).Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci USA 104: 17204-17209.
13. Thakker, DR, Natt, F, Hüsken, D, Maier, R, Müller, M, van der Putten, H et al. (2004).Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc Natl Acad Sci USA 101: 17270-17275.
14. Burgess, A, Huang, Y, Querbes, W, Sah, DW and Hynynen, K (2012).Focused ultrasound for targeted delivery of siRNA and efficient knockdown of Htt expression. J Control Release 163: 125-129.
15. Stiles, DK, Zhang, Z, Ge, P, Nelson, B, Grondin, R, Ai, Y et al. (2012).Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exp Neurol 233: 463-471.
16. Dass, CR (2002).Cytotoxicity issues pertinent to lipoplex-mediated gene therapy in-vivo. J Pharm Pharmacol 54: 593-601.
17. Karra, D and Dahm, R (2010).Transfection techniques for neuronal cells. J Neurosci 30: 6171-6177.
18. Song, H and Yang, PC (2010).Construction of shRNA lentiviral vector. N Am J Med Sci 2: 598-601.
19. Tomar, RS, Matta, H and Chaudhary, PM (2003).Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene 22: 5712-5715.
20. Bell, H, Kimber, WL, Li, M and Whittle, IR (1998).Liposomal transfection efficiency and toxicity on glioma cell lines: in vitro and in vivo studies. Neuroreport 9: 793-798.
21. Masotti, A, Mossa, G, Cametti, C, Ortaggi, G, Bianco, A, Grosso, ND et al. (2009).Comparison of different commercially available cationic liposome-DNA lipoplexes: Parameters influencing toxicity and transfection efficiency. Colloids Surf B Biointerfaces 68: 136-144.
22. Zou, LL, Huang, L, Hayes, RL, Black, C, Qiu, YH, Perez-Polo, JR et al. (1999).Liposomemediated NGF gene transfection following neuronal injury: potential therapeutic applications. Gene Ther 6: 994-1005.
23. Kordasiewicz, HB, Stanek, LM, Wancewicz, EV, Mazur, C, McAlonis, MM, Pytel, KA et al. (2012).Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 74: 1031-1044.
24. Birmingham, A, Anderson, E, Sullivan, K, Reynolds, A, Boese, Q, Leake, D et al. (2007).A protocol for designing siRNAs with high functionality and specificity. Nat Protoc 2: 2068-2078.
25. Reynolds, A, Leake, D, Boese, Q, Scaringe, S, Marshall, WS and Khvorova, A (2004).Rational siRNA design for RNA interference. Nat Biotechnol 22: 326-330.
26. Byrne, M, Tzekov, R, Wang, Y, Rodgers, A, Cardia, J, Ford, G et al. (2013).Novel hydrophobically modified asymmetric RNAi compounds (sd-rxRNA) demonstrate robust efficacy in the eye. J Ocul Pharmacol Ther 29: 855-864.
27. Geary, RS, Norris, D, Yu, R and Bennett, CF (2015).Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev 87: 46-51.
28. Khvorova, A, Kamens, J, Samarsky, D, Woolf, T, Cardia, J (2014).Reduced size selfdelivering RNAi compounds. US patent 20120040459.
29. Soutschek, J, Akinc, A, Bramlage, B, Charisse, K, Constien, R, Donoghue, M et al. (2004).Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178.
30. Judge, AD, Bola, G, Lee, AC and MacLachlan, I (2006).Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 13: 494-505.
31. Dolga, AM, Granic, I, Blank, T, Knaus, HG, Spiess, J, Luiten, PG et al. (2008).TNFalpha-mediates neuroprotection against glutamate-induced excitotoxicity via NF-kappaBdependent up-regulation of K2.2 channels. J Neurochem 107: 1158-1167.
32. De Paula, D, Bentley, MV and Mahato, RI (2007).Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 13: 431-456.
33. Watts, JK, Deleavey, GF and Damha, MJ (2008).Chemically modified siRNA: tools and applications. Drug Discov Today 13: 842-855.
34. Watts, JK and Corey, DR (2012).Silencing disease genes in the laboratory and the clinic. J Pathol 226: 365-379.
35. Deleavey, F and Damha, MJ (2012).Designing chemically modified oligonucleotides for targeted gene silencing. Chem Biol 19: 937-954.
36. Li, SH, Schilling, G, Young, WS 3rd, Li, XJ, Margolis, RL, Stine, OC et al. (1993).Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron 11: 985-993.
37. Foster, DJ, Barros, S, Duncan, R, Shaikh, S, Cantley, W, Dell, A et al. (2012).Comprehensive evaluation of canonical versus Dicer-substrate siRNA in vitro and in vivo. RNA 18: 557-568.
38. Song, E, Lee, SK, Dykxhoorn, DM, Novina, C, Zhang, D, Crawford, K et al. (2003).Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J Virol 77: 7174-7181.
39. Mullen, RJ, Buck, CR and Smith, AM (1992).NeuN, a neuronal specific nuclear protein in vertebrates. Development 116: 201-211.
40. Weyer, A and Schilling, K (2003).Developmental and cell type-specific expression of the neuronal marker NeuN in the murine cerebellum. J Neurosci Res 73: 400-409.
41. Marques, JT and Williams, BR (2005).Activation of the mammalian immune system by siRNAs. Nat Biotechnol 23: 1399-1405.
42. Imai, Y, Ibata, I, Ito, D, Ohsawa, K and Kohsaka, S (1996).A novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage. Biochem Biophys Res Commun 224: 855-862.
43. Garden, GA and Möller, T (2006).Microglia biology in health and disease. J Neuroimmune Pharmacol 1: 127-137.
44. Shitaka, Y, Tran, HT, Bennett, RE, Sanchez, L, Levy, MA, Dikranian, K et al. (2011).Repetitive closed-skull traumatic brain injury in mice causes persistent multifocal axonal injury and microglial reactivity. J Neuropathol Exp Neurol 70: 551-567.
45. Brown, GC and Neher, JJ (2010).Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol Neurobiol 41: 242-247.
46. Ferrazzano, P, Chanana, V, Uluc, K, Fidan, E, Akture, E, Kintner, DB et al. (2013).Agedependent microglial activation in immature brains after hypoxia-ischemia. CNS Neurol Disord Drug Targets 12: 338-349.
47. Koshinaga, M, Suma, T, Fukushima, M, Tsuboi, I, Aizawa, S and Katayama, Y (2007).Rapid microglial activation induced by traumatic brain injury is independent of blood brain barrier disruption. Histol Histopathol 22: 129-135.
48. Ouimet, CC, Miller, PE, Hemmings, HC Jr, Walaas, SI and Greengard, P (1984).DARPP-32, a dopamine-and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization. J Neurosci 4: 111-124.
49. Bartlett, DW and Davis, ME (2006).Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res 34: 322-333.
50. Carroll, JB, Warby, SC, Southwell, AL, Doty, CN, Greenlee, S, Skotte, N et al. (2011).Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. Mol Ther 19: 2178-2185.
51. Southwell, AL, Skotte, NH, Kordasiewicz, HB, Estergaard, ME, Watt, AT, Carroll, JB et al. (2014).In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. Mol Ther 22: 2093-2106.
52. Southwell, AL, Smith, SE, Davis, TR, Caron, NS, Villanueva, EB, Xie, Y et al. (2015).Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Sci Rep 5: 12166.
53. Alvarez-Erviti, L, Seow, Y, Yin, H, Betts, C, Lakhal, S and Wood, MJ (2011).Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29: 341-345.
54. Marcus, ME and Leonard, JN (2013).FedExosomes: engineering therapeutic biological nanoparticles that truly deliver. Pharmaceuticals (Basel) 6: 659-680.
55. Anderson, E, Boese, Q, Khvorova, A and Karpilow, J (2008).Identifying siRNA-induced off-targets by microarray analysis. Methods Mol Biol 442: 45-63.
56. Schwarz, DS, Hutvágner, G, Du, T, Xu, Z, Aronin, N and Zamore, PD (2003).Asymmetry in the assembly of the RNAi enzyme complex. Cell 115: 199-208.
57. Khvorova, A, Reynolds, A and Jayasena, SD (2003).Functional siRNAs and miRNAs exhibit strand bias. Cell 115: 209-216.
58. DiFiglia, M, Sapp, E, Chase, K, Schwarz, C, Meloni, A, Young, C et al. (1995).Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 14: 1075-1081.